Dendreon, the Seattle company developing an immune-stimulating therapy for prostate cancer, said today it has started a clinical trial of a cancer drug made in a more conventional pill form. The company will examine safety of D3263 at a variety of doses in patients with solid tumors. Dendreon has been advancing this program toward clinical trials to diversify its pipeline beyond Provenge, its lead drug candidate, which succeeded in a clinical trial earlier this month.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
